Does prospective statin administration prevent LVEF declines 2 years after doxorubicin treatment in patients with breast cancer and lymphoma?
Patients with breast cancer and lymphoma with no existing indication for statin therapy receiving doxorubicin
Prospective statin administration
Left ventricular ejection fraction (LVEF) declines 2 years after doxorubicinsurrogate
Prospective statin therapy does not prevent declines in left ventricular ejection fraction at 2 years in patients receiving doxorubicin for breast cancer or lymphoma.
In patients with breast cancer and lymphoma with no existing indication for statin therapy, prospective statin administration did not affect LVEF declines 2 years after doxorubicin. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01988571.).
Building similarity graph...
Analyzing shared references across papers
Loading...
W. Gregory Hundley
Ralph B. D’Agostino
Teresa Crotts
NEJM Evidence
University of Washington
University of Pennsylvania
National Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Hundley et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69da26158988aeabbe686a2a — DOI: https://doi.org/10.1056/evidoa2200097
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: